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Abstract Thromboelastometry is increasingly used in the
clinical and scientific setting. The use of frozen plasma
samples may be useful in overcoming certain limitations
such as local and timely availability. Whole blood (WB)
samples of 20 healthy volunteers were obtained, and
plasma was generated. NATEM (n = 20), EXTEM
(n = 20) and INTEM (n = 8) analyses were performed in
WB, fresh plasma and frozen and thawed plasma. Dabi-
gatran (500, 1000 ng/ml), rivaroxaban (100, 200 ng/ml) or
alteplase (333 ng/ml) were added ex vivo to WB, and
thromboelastometry was performed in WB and in frozen
and thawed plasma samples. Clot formation time, mean
clot firmness and the area under the curve were signifi-
cantly altered in plasma compared to WB. In INTEM and
EXTEM analysis, clotting time (CT) was comparable
between WB (100%) and fresh (INTEM 114% and
EXTEM 93%, ratio of the means) and frozen plasma
samples (85 and 99%), whereas in NATEM analysis, the
CT increased in fresh (193%) and frozen plasma samples
(130%). Dabigatran dose-dependently increased the CT
approximately 5- and 9-fold in WB and even more pro-
nounced 10- and 26-fold in plasma. Accordingly, rivarox-
aban dose-dependently increased the CT 2- and 2.7-fold in
WB, and 3.5- and 4-fold in plasma samples. Hyperfibri-
nolysis was achieved by addition of alteplase in all WB
samples and was reproducible in plasma samples. In con-
clusion, thromboelastometry, especially INTEM and
EXTEM analyses, is possible using frozen and stored
plasma samples with comparable results to the corre-
sponding whole blood samples.
Keywords Thromboelastometry  Hyperfibrinolysis 
Coagulation  Blood  Blood plasma  Direct oral
anticoagulants  Coagulation
List of abbreviations
AUC Area under the curve
C Celsius
CT Clotting time
CFT Clot formation time
MCF Maximum clot firmness
ML Maximum lysis
LT Time of maximum lysis
Introduction
Thromboelastometry is a point-of-care assay measuring the
viscoelastic properties of clot formation and clot lysis of
whole blood [1]. The results of such measurements offer
quick information about the global coagulation profile [2].
This may be useful in certain clinical situations, i.e.,
during surgery, in bleeding patients, in patients with
hemorrhagic disorders, to monitor certain drugs or when
massive transfusions are required [3–9]. Furthermore, the
impact of hemostatic interventions can be rapidly assessed
and decisions may be based on results of such viscoelastic
tests [10]. The advantages of thromboelastometry-guided
hemostatic therapy were demonstrated in patients under-
going cardiac surgery [11]. Blood loss and the need for
fresh frozen plasma units could be reduced. Moreover, the
perioperative need of blood products could be reduced in
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patients with severe burn injuries [12]. The diagnosis of
hyperfibrinolysis is often difficult and testing the vis-
coelastic properties of blood may offer important infor-
mation to support the diagnosis [13, 14] or to diagnose
hyperfibrinolytic disseminated intravascular coagulation
[15]. Thromboelastometry is also sensitive to anticoagulant
drugs such as enoxaparin [16], apixaban, rivaroxaban,
argatroban and dabigatran [17–19].
Thromboelastometry is sensitive to the coagulation
activation in the human endotoxemia model [20] and may
be used to identify prothrombotic states in patients [21–23].
However, like every other testing system some limita-
tions need to be considered. First of all, thromboelastom-
etry produced accurate and reproducible results within
30 min up to 4 h, but inconsistent references are published
on the stability and reproducibility of measurements after
sample storage at room temperature [24–26]. The intra-
individual coefficient of variation of thromboelastometry
ranged between 11 and 23% in healthy volunteers (own
unpublished data). Secondly, trained personnel and avail-
able devices are necessary. In the clinical setting, usually
rapid results are required which is an important advantage
of this method. On the contrary, in the scientific setting,
storage of samples for later batch analysis offers obvious
advantages.
The aim of this study was to investigate whether the
results of thromboelastometry performed on frozen plasma
samples are comparable to the results obtained from freshly
obtained whole blood. This may help to overcome at least
part of these limitations.
Methods
This study was performed at the Department of Clinical
Pharmacology at the Medical University of Vienna. The
independent Ethics Committee of the Medical University
of Vienna approved the study. Twenty healthy volunteers
were included in the study, and blood sampling was per-
formed between February and April 2016 (Table 1).
Preparation of whole blood and plasma samples
Whole blood samples were obtained from fresh
venipunctures in healthy volunteers and collected into
3.8% sodium citrate tubes.
To generate platelet-free plasma, whole blood was
centrifuged twice at 2500g for 15 min at room temperature
and the supernatant was transferred into polypropylene
tubes. Plasma samples were either used for immediate
analysis (fresh plasma) or frozen and stored as explained
below (frozen plasma).
To investigate the effects of freezing on hyperfibrinol-
ysis, we spiked alteplase (actilyse, 333 ng/ml) into whole
blood samples to induce artificial hyperfibrinolysis.
ROTEM analysis was performed for fresh blood, and again
plasma was generated for immediate (fresh plasma) or later
(frozen plasma) analysis as explained above.
To investigate the effects of oral anticoagulants, we
spiked rivaroxaban (100 and 200 ng/ml) and dabigatran
(500 and 1000 ng/ml) into whole blood and performed
ROTEM analysis. Again plasma for immediate and later
analysis was generated from the whole blood samples as
explained above.
Plasma samples of all 20 healthy volunteers were frozen
and stored at -80 C until later analysis. These samples
included native plasma and plasma containing rivaroxaban,
dabigatran and alteplase, as explained above.
Additionally, we investigated whether different freezing
techniques and storage temperatures affected the results of
ROTEM analysis. Therefore, plasma of eight healthy vol-
unteers was frozen using dry ice (-78 C) and then
transferred to -80 or -18 C storage. Plasma samples of
another eight subjects were frozen and stored at -18 C,
and plasma samples of another eight subjects were frozen
using liquid nitrogen (-196 C) and then transferred to
-80 or -18 C storage.
All frozen plasma samples were thawed using a water
bath heated to 37 C (C) for 15 min and analyzed there-
after. Whole blood and fresh plasma samples were tested at
the same time, whereas frozen plasma samples were ana-
lyzed at one to four weeks later.
Thromboelastometry
The viscoelastic properties of whole blood or plasma were
investigated with the ROTEM coagulation analyzer (Pen-
tapharm, Munich, Germany) as previously described [20].
In short, ROTEM measures shear elastic modulus during
clot formation and subsequent fibrinolysis. The ROTEM
uses a ball-bearing system for power transduction, which
makes it less susceptible to mechanical stress, movement
and vibration.
Table 1 Demographics and baseline data of participants
Parameters Mean ± SD
Gender m (f) 11 (9)
Age (years) 26 ± 5
Height (cm) 174 ± 10
Weight (kg) 72 ± 17
Hemoglobin (g/dl) 14.1 ± 1.3
Platelets (*10^9) 265 ± 59
Leukocytes (*10^9) 5.9 ± 1.3
Baseline data and demographics are presented (means ± SD)
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ROTEM measurements produced accurate and repro-
ducible results within 30 min up to 4 h. In fresh blood
samples, we performed ROTEM measurements between 1
and 2 h after blood storage at room temperature.
Just before running the assay, citrated blood samples were
recalcified with 20 ll of CaCl2 0.2 M (Start-TEM; Nobis,
Endingen, Germany) and the test was started. We performed
thromboelastometry without adding additional activators
(NATEM), as well as EXTEM analysis (recombinant tissue
factor- and phospholipid-activated ROTEM), and in eight
subjects INTEM analysis (partial thromboplastin–phospho-
lipid-activated ROTEM). The following ROTEM parame-
ters were analyzed: the clotting time (CT), the clot formation
time (CFT), the maximum clot firmness (MCF), the alpha
angle (alpha), the maximum lysis (ML), the time of maxi-
mum lysis (LT) and the area under the curve (AUC).
In samples with alteplase, dabigatran or rivaroxaban,
only EXTEM analysis was performed.
ROTEM analysis in frozen plasma samples was gener-
ally technically feasible. However, one problem regularly
occurred in the testing system and an error code was
reported that the stability of the clot rapidly increased and
the sample dried. All tests were running for 2 h. This
problem may have affected the detection of ML and the
AUC, because these parameters are measured continuously
until the end of the chosen running time.
Of note, the clot signal amplitude did not reach 20 mm
in all plasma samples resulting in no measurable CFT.
Statistical analysis
A formal sample size calculation was not performed,
because no data on this topic were available. We performed
nonparametric testing using the Friedman ANOVA for
overall comparisons and the Mann–Whitney-U test for
group-wise comparisons. Descriptive statistics are pre-




Table 2 presents the results of ROTEM analysis performed
in whole blood samples, fresh and frozen plasma samples.
Whole blood versus fresh and frozen plasma
NATEM
The CT was approximately 50% shorter in whole blood
compared to fresh plasma (p\ 0.001) and 25% compared
to frozen plasma samples (p = 0.003). Interestingly, the
CT was also shorter in frozen plasma samples compared to
fresh plasma (p = 0.005). The CFT was approximately
two-fold longer in fresh or frozen plasma compared to
whole blood (p\ 0.001). Expectedly, MCF and AUC were
approximately two-fold higher in whole blood than in
plasma samples due to a lack of blood cells (p\ 0.001).
EXTEM
The CT was similar between whole blood, fresh and frozen
plasma samples. However, a trend to a shorter CT was
noticeable in fresh plasma samples (p = 0.086). Individual
CTs are shown in Fig. 1. The CFT was 8- to 9-fold longer
in fresh and frozen plasma samples compared to whole
blood, respectively (p\ 0.001). Alpha angles were
approximately 10% higher in plasma samples compared to
whole blood (p\ 0.001). Expectedly, the AUC and the
MCF were approximately 2.5-fold higher in whole blood
compared to fresh or frozen plasma samples (p\ 0.001).
Similar to NATEM analysis, measurement of ML was not
feasible in plasma samples.
INTEM
The CT was similar between whole blood and fresh or
frozen plasma samples. However, the CT in frozen plasma
was shorter than in fresh plasma samples (p = 0.006). The
CFT was 9- to 15-fold longer in fresh and frozen plasma
samples compared to whole blood, respectively (p = 0.01
and p = 0.014). The alpha angle was 10% smaller in whole
blood and fresh plasma samples compared to frozen plasma
samples (p = 0.008 and p = 0.042, respectively). Similar
Fig. 1 Individual clotting times in EXTEM analysis using whole
blood, plasma and frozen and thawed plasma (plasma—stored















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to NATEM and EXTEM analysis, the MCF (p B 0.001)
and the AUC (p\ 0.03) were approximately 2.5-fold
higher in whole blood compared to plasma samples.
Freezing methods
NATEM
The CT was similar for whole blood and plasma frozen and
stored at -18 C and for plasma frozen in dry ice and
stored at -80 C, but significantly longer for plasma frozen
and stored at -80 C (p = 0.003), frozen with dry ice and
stored at -18 C (p = 0.003), frozen with liquid nitrogen
and stored at -18 C (p = 0.004) and frozen with liquid
nitrogen and stored at -80 C (p = 0.001) (Table 3). The
CFT was significantly longer in plasma samples compared
to whole blood, except for samples frozen and stored at
-18 C. Expectedly, the AUC, MCF and alpha angles
were significantly smaller in plasma compared to whole
blood, except for the alpha angles measured in samples
frozen and stored at -18 C. Again, ML was not
measureable.
EXTEM
The CT was shorter in samples frozen and stored at
-18 C compared to whole blood (p = 0.025), but similar
for all other freezing and storage methods. The CFT was
significantly longer in all plasma samples, the AUC and the
MCF were significantly smaller compared to whole blood.
Alpha angles were approximately 10% larger in all plasma
samples compared to whole blood.
Dabigatran and rivaroxaban anticoagulation
Expectedly, ex vivo addition of dabigatran and rivaroxaban
to whole blood prolonged the CT significantly and con-
centration-dependently in whole blood and in plasma
samples (Fig. 2). The CT and CFT of plasma samples were
significantly longer for plasma samples compared to whole
blood samples (Fig. 2, p\ 0.001 for both dabigatran,
rivaroxaban concentrations: p = 0.019 for 100 ng/mL,
p = 0.021 for 200 ng/mL). The MCF and the AUC were
significantly smaller in plasma samples compared to whole
blood (p\ 0.001 for all tests). The alpha angle was larger
in plasma samples compared to whole blood (p\ 0.001).
Hyperfibrinolysis
Almost complete clot lysis occurred in whole blood sam-
ples, which was well reproducible in plasma samples
(Table 4). Whole blood and plasma samples differed for
CFT, MCF and the AUC. However, CT, ML and LT were
similar.
Discussion
We investigated whether ROTEM analysis performed in
frozen, stored and thawed plasma samples provides similar
results compared to whole blood samples. We only found
few reports performing thromboelastometry in human
plasma samples [27–30]. Based on these, we expected a
smaller MCF, a prolonged CFT and a reduced AUC due to
a lack of blood cells. Clotting time was comparable in
EXTEM and, to a lesser degree, in INTEM analysis.
In EXTEM analysis, the CT tended to be shorter in
plasma samples. This difference, although statistically
significant, was minor, and the clinical relevance is at least
questionable. Of note, all results were within the reference
values suggested by the manufacturer (43–82 s) [31].
Moreover, another study measured a relatively short
median CT of 47 s in EXTEM analysis using platelet free
plasma [27].
In contrast to EXTEM, INTEM and NATEM analysis
showed a prolonged CT in fresh plasma samples compared
to whole blood. INTEM analysis uses a less potent acti-
vator compared to EXTEM analysis, while NATEM anal-
ysis does not involve any activator. This suggests that in
the absence of strong activators pro-coagulant surfaces
seem to be more important for the initiation of the coag-
ulation cascade. Indeed, in some samples coagulation
Fig. 2 Clotting times after addition of dabigatran and rivaroxaban to
whole blood and plasma. Whole blood was spiked in vitro with two
doses of dabigatran (500 and 1000 ng/ml) or rivaroxaban (100 and
200 ng/ml). After EXTEM analysis was performed in whole blood,
the sample was centrifuged, frozen and stored at -80 C. Frozen
plasma samples were thawed, and EXTEM analysis was performed.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































activation did not occur at all or was prolonged to more
than 3000 s. The CT of NATEM analysis in whole blood
was longer in our population (856 ± 233 s) compared to
the manufacturer’s reference values (254–837 s) [31] and
compared to other studies [20, 32]. However, the vari-
ability of results in the non-activated thromboelastometry
analysis was similar to these studies.
We furthermore investigated various freezing methods
in a small number of samples (n = 8), and except for
samples frozen and stored at -18 C and the samples
frozen in dry ice and stored at -80 C, the CT in NATEM
analysis was 40–60% longer compared to whole blood
samples. In EXTEM analysis, no differences were
detectable except for the samples frozen and stored at
-18 C, in which the CT was *10% shorter. It is con-
ceivable that freezing, storage and/or thawing procedures
have an impact on the results. One possible explanation for
the varying results may be cold or contact activation of
coagulation factors, which was shown for factor V, VIII,
XII and consecutive thrombin generation [33, 34]. To
minimize the influence of such factors, we applied a strict
freezing and thawing schedule. We used citrate-anticoag-
ulated blood samples as suggested by the manufacturer.
However, in contrast to citrate, corn trypsin inhibitor suf-
ficiently suppressed contact activation in calibrated auto-
mated thrombin generation [35–37]. Thus, it is possible
that the use of corn trypsin inhibitor could improve the
reproducibility of results. Numerically, the shortest CT of
all plasma samples was measured in samples frozen and
stored at -18 C. Cold activation may have played the
biggest part in these samples, because freezing itself takes
longer than with snap-freezing. We therefore cannot rec-
ommend freezing and storing samples at -18 C.
Considering our results and given the limited availability of
fluid N2 and dry ice, we recommend freezing and storing of
plasma samples at -80 C.
Residual platelet counts affect global coagulation tests
or coagulation factors only by a small margin [38]. How-
ever, we hypothesized that in the non-activated setting, the
presence of pro-coagulatory surfaces may be of greater
importance. To obtain platelet-free plasma, we performed
two centrifugation steps at 2500g. We measured platelet
counts in a smaller number of plasma samples and detected
a median platelet count \1 G/L. However, we cannot
exclude entirely that very low platelet counts occurred in
some samples. Thus, disintegration of any residual platelets
and consecutive exposure to phospholipids may have led to
the shorter clotting time in frozen plasma samples [39].
The influence of dabigatran and rivaroxaban on vis-
coelastic properties of whole blood was demonstrated
previously [17, 40]. In plasma samples, the CT was further
increased compared to whole blood. As we used the same
whole blood samples for plasma generation as for ROTEM
analysis, the concentration itself remained equal. It seems
likely that in the presence of coagulation inhibitors such as
rivaroxaban or dabigatran, the activator used in EXTEM
analysis may not be potent enough to initiate coagulation
and the lack of pro-coagulant surfaces becomes relevant.
The CT is therefore further prolonged. Due to the magni-
tude of the observed effects, the use of frozen plasma
samples in EXTEM analysis to investigate the presence of
inhibitors of coagulation such as rivaroxaban or dabigatran
seems especially suitable.
Thromboelastometry may be used as a supportive tool in
the diagnosis of hyperfibrinolysis [14]. To artificially
induce hyperfibrinolysis, we spiked alteplase into blood
Table 4 Results of EXTEM analysis after addition of alteplase
Whole blood samples (n = 10) Plasma -80 (n = 10) Individual % of whole blood (mean ± SD) p value
CT (s) 69 ± 9 64 ± 9 109 ± 17% n.s.
CFT (s) 91 ± 23 422 ± 270a 40 ± 47% 0.001
MCF (mm) 52 ± 6 19 ± 5* 300 ± 91% \0.001
Alpha angle () 72 ± 4 72 ± 25* 92 ± 4% 0.003
ML (%) 100 ± 0 99 ± 3 101 ± 3% n.s.
AUC 5188 ± 605 1822 ± 453* 301 ± 85% \0.001
LT (s) 1655 ± 1129 1053 ± 340 138 ± 49% n.s.
This table presents the results (means ± SD) of EXTEM analysis after alteplase (333 ng/ml) was added to whole blood samples. After analysis
was performed, plasma was generated, frozen and stored at -80 C, and thawed for analysis. CT and clot lysis-specific parameters ML and LT
were not different between whole blood and plasma samples
CT clotting time, CFT clot formation time, MCF maximum clot firmness, Alpha alpha angle, ML maximum lysis, AUC area under the curve, LT
time of maximum lysis, n.s. not significant
* p\ 0.05
a A clot signal amplitude of 20 mm was not reached in all samples
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samples as described earlier [13, 41]. Hyperfibrinolysis was
reproducible in frozen and stored plasma samples with a
shorter time of maximum lysis in plasma samples. A likely
explanation may be the reduced MCF in plasma samples
with quicker complete lysis of the smaller clot. Interest-
ingly, no difference was detected in the CT of plasma
samples compared to whole blood indicating the repro-
ducibility of the results. However, due to the mentioned
technical limitations caused by the regular clotting of the
entire sample, we assume that only hyperfibrinolysis of a
certain extent is detectable in plasma samples. As we
included only healthy volunteers with minimal clot lysis
and a usually late onset of clot lysis in our study, we were
not able to detect any form of clot lysis. In hyperfibri-
nolytic patients, lysis occurs within 30 min with a complete
clot lysis within 60 min [14]. This faster onset and the
strong fibrinolysis should be initiated and therefore be
detectable before the sample has clotted entirely. However,
this needs to be confirmed in studies investigating hyper-
fibrinolysis in patients.
This study has several limitations. First of all, the
sample size of 20, and in some instances 8, may be too
small to detect differences or may be affected by outliers.
Furthermore, we did not perform global or more specific
coagulation tests before inclusion in the study or in thawed
plasma samples. When ROTEM was performed in plasma
samples, the error ‘‘dried plasma sample’’ occurred regu-
larly, which probably affected measurement of low level
ML. We only included healthy volunteers in our study.
Possibly in thrombophilic conditions, NATEM analysis is
more reliable due to the presence of activators of coagu-
lation such as tissue factor.
In conclusion, thromboelastometry may be performed in
frozen, stored and thawed plasma samples taking the
mentioned limitations into account. Activated ROTEM
tests such as INTEM or EXTEM are reproducible, and
results are comparable between whole blood and corre-
sponding fresh and frozen plasma, whereas non-activated
NATEM analysis is subject to greater variability. Our test
setup was suitable to detect potent hyperfibrinolysis with a
rapid onset and the presence of anticoagulants.
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